Latest Breaking News On - Peter choo - Page 1 : comparemela.com

Malaysian Patent Granted for CytoMed Therapeutics Licensed Allogeneic CAR-Gamma Delta T Cell Technology

29.01.2024 - The Company now has exclusive rights to a Malaysia, US and China patentSINGAPORE, Jan. 29, 2024 (GLOBE NEWSWIRE) - CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on . Seite 1

Peter chooCytomed therapeutics limitedCytomed or companyProperty corporation of malaysiaExchange commissionMed therapeutics limitedIntellectual property corporationDeltat cellsTumoricidal activityLicense agreementCytomed therapeutics chartYtomed therapeutics kursYtomed therapeutics aktie

Malaysian Patent Granted for CytoMed Therapeutics Licensed Allogeneic CAR-Gamma Delta T Cell Technology

Malaysian Patent Granted for CytoMed Therapeutics Licensed Allogeneic CAR-Gamma Delta T Cell Technology
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Peter chooExchange commissionProperty corporation of malaysiaAgency for scienceCytomed therapeutics limitedCytomed or companyDrug administrationPatent grantedCytomed therapeutic licensed allogeneicGamma deltat cellMed therapeutics limitedIntellectual property corporationDeltat cellsTumoricidal activityLicense agreementPrivate securities litigation reform act

Foundation brings orthopaedic care to over 50 elderly Kelabit, Penan patients

Foundation brings orthopaedic care to over 50 elderly Kelabit, Penan patients
theborneopost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theborneopost.com Daily Mail and Mail on Sunday newspapers.

Datin pearl masnaPenghulu caleena sakaiPeter chooAustralian high commissionYayasan kesenian orang asliKesenian orang asliCaleena sakaiMiri hospitalAustralian high

CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update

Conference call webcast is scheduled for November 22 at 9 a.m. ET. SINGAPORE, Nov. 17, 2023 /PRNewswire/ CytoMed Therapeutics Limited , a Singapore-based biopharmaceutical company focused on.

National university hospitalSingapore generalPeter chooHealth sciences authorityCytomed therapeutics limitedCytomed therapeuticsAgency for scienceCytomed or companyGood manufacturing practiceSix months ended junePublic offeringCash equivalentsPrivate securities litigation reform actAmed therapeutics

CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update

Conference call webcast is scheduled for November 22 at 9 a.m. ET. SINGAPORE, Nov. 17, 2023 /PRNewswire/ CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced its first half of 2023 financial results.

National university hospitalSingapore generalPeter chooCytomed or companyHealth sciences authorityCytomed therapeutics limitedAgency for scienceGood manufacturing practiceSix months ended junePublic offeringCash equivalents